Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 16/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17056036 | 0.90 | TTK (0.43) | TTKCCNA2CDK2HASPINFGFR4 | |
| SCHEMBL17056052 | 0.86 | TTK (0.47) | TTKCCNA2CDK2HASPINFGFR4 | |
| SCHEMBL17056040 | 0.83 | TTK (0.48) | TTKCCNA2CDK2HASPIN | |
| SCHEMBL18300182 | 0.76 | TTK (0.44) | TTKCCNA2CDK2 | |
| SCHEMBL17056033 | 0.75 | TTK (0.49) | TTKMEN1KMT2A | |
| SCHEMBL29577170 | 0.75 | TTK (0.37) | TTKCCNA2CDK2FGFR4 | |
| SCHEMBL20331105 | 0.75 | TTK (0.37) | TTKCCNA2CDK2FGFR4 | |
| SCHEMBL21252146 | 0.74 | TTK (0.37) | TTKCCNA2CDK2FGFR4 | |
| SCHEMBL30768106 | 0.70 | HASPIN (0.42) | TTKHASPINMEN1KMT2A | |
| SCHEMBL30768104 | 0.70 | HASPIN (0.42) | TTKHASPINMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3110816-B1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| EP-3110816-B1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2015128676-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | TTK 19/4885CCNA2 312/4885CDK2 24/4885 |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | TTK 19/4885CCNA2 312/4885CDK2 24/4885 |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | BUB1, BUB1B, CDK1 | TTK 19/4885CCNA2 312/4885CDK2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.